nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—migraine—Prednisone—psoriatic arthritis	0.282	0.341	CpDpCtD
Cyclobenzaprine—osteoarthritis—Methylprednisolone—psoriatic arthritis	0.273	0.33	CpDpCtD
Cyclobenzaprine—osteoarthritis—Prednisone—psoriatic arthritis	0.273	0.33	CpDpCtD
Cyclobenzaprine—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0194	0.216	CbGbCtD
Cyclobenzaprine—CYP3A4—Triamcinolone—psoriatic arthritis	0.0147	0.164	CbGbCtD
Cyclobenzaprine—CYP3A4—Betamethasone—psoriatic arthritis	0.0126	0.141	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisolone—psoriatic arthritis	0.0124	0.139	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisone—psoriatic arthritis	0.0117	0.131	CbGbCtD
Cyclobenzaprine—CYP2D6—Dexamethasone—psoriatic arthritis	0.0115	0.129	CbGbCtD
Cyclobenzaprine—CYP3A4—Dexamethasone—psoriatic arthritis	0.00733	0.0817	CbGbCtD
Cyclobenzaprine—Angioedema—Triamcinolone—psoriatic arthritis	0.000184	0.00221	CcSEcCtD
Cyclobenzaprine—Angioedema—Methylprednisolone—psoriatic arthritis	0.000184	0.0022	CcSEcCtD
Cyclobenzaprine—Hallucination—Prednisone—psoriatic arthritis	0.000182	0.00218	CcSEcCtD
Cyclobenzaprine—Malaise—Triamcinolone—psoriatic arthritis	0.000182	0.00218	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Methotrexate—psoriatic arthritis	0.000181	0.00217	CcSEcCtD
Cyclobenzaprine—Malaise—Methylprednisolone—psoriatic arthritis	0.000181	0.00217	CcSEcCtD
Cyclobenzaprine—Vertigo—Triamcinolone—psoriatic arthritis	0.000181	0.00217	CcSEcCtD
Cyclobenzaprine—Syncope—Triamcinolone—psoriatic arthritis	0.000181	0.00217	CcSEcCtD
Cyclobenzaprine—Vertigo—Methylprednisolone—psoriatic arthritis	0.00018	0.00216	CcSEcCtD
Cyclobenzaprine—Syncope—Methylprednisolone—psoriatic arthritis	0.00018	0.00216	CcSEcCtD
Cyclobenzaprine—Oedema—Prednisolone—psoriatic arthritis	0.000179	0.00214	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000179	0.00214	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.000177	0.00213	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000177	0.00212	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000177	0.00212	CcSEcCtD
Cyclobenzaprine—Shock—Prednisolone—psoriatic arthritis	0.000176	0.00211	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.000176	0.00211	CcSEcCtD
Cyclobenzaprine—Convulsion—Triamcinolone—psoriatic arthritis	0.000174	0.00209	CcSEcCtD
Cyclobenzaprine—Tachycardia—Prednisolone—psoriatic arthritis	0.000174	0.00209	CcSEcCtD
Cyclobenzaprine—Convulsion—Methylprednisolone—psoriatic arthritis	0.000174	0.00209	CcSEcCtD
Cyclobenzaprine—Hypertension—Triamcinolone—psoriatic arthritis	0.000174	0.00208	CcSEcCtD
Cyclobenzaprine—Hypertension—Methylprednisolone—psoriatic arthritis	0.000173	0.00208	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000173	0.00207	CcSEcCtD
Cyclobenzaprine—Myalgia—Triamcinolone—psoriatic arthritis	0.000171	0.00206	CcSEcCtD
Cyclobenzaprine—Myalgia—Methylprednisolone—psoriatic arthritis	0.000171	0.00205	CcSEcCtD
Cyclobenzaprine—Anxiety—Methylprednisolone—psoriatic arthritis	0.00017	0.00204	CcSEcCtD
Cyclobenzaprine—Drowsiness—Methotrexate—psoriatic arthritis	0.00017	0.00204	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000169	0.00203	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000169	0.00203	CcSEcCtD
Cyclobenzaprine—Discomfort—Triamcinolone—psoriatic arthritis	0.000169	0.00203	CcSEcCtD
Cyclobenzaprine—Discomfort—Methylprednisolone—psoriatic arthritis	0.000169	0.00203	CcSEcCtD
Cyclobenzaprine—Dry mouth—Triamcinolone—psoriatic arthritis	0.000168	0.00201	CcSEcCtD
Cyclobenzaprine—Angioedema—Dexamethasone—psoriatic arthritis	0.000167	0.002	CcSEcCtD
Cyclobenzaprine—Angioedema—Betamethasone—psoriatic arthritis	0.000167	0.002	CcSEcCtD
Cyclobenzaprine—Stomatitis—Methotrexate—psoriatic arthritis	0.000166	0.00199	CcSEcCtD
Cyclobenzaprine—Confusional state—Methylprednisolone—psoriatic arthritis	0.000165	0.00198	CcSEcCtD
Cyclobenzaprine—Malaise—Betamethasone—psoriatic arthritis	0.000165	0.00198	CcSEcCtD
Cyclobenzaprine—Malaise—Dexamethasone—psoriatic arthritis	0.000165	0.00198	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000164	0.00197	CcSEcCtD
Cyclobenzaprine—Oedema—Triamcinolone—psoriatic arthritis	0.000164	0.00197	CcSEcCtD
Cyclobenzaprine—Vertigo—Dexamethasone—psoriatic arthritis	0.000164	0.00197	CcSEcCtD
Cyclobenzaprine—Vertigo—Betamethasone—psoriatic arthritis	0.000164	0.00197	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000164	0.00197	CcSEcCtD
Cyclobenzaprine—Syncope—Dexamethasone—psoriatic arthritis	0.000164	0.00196	CcSEcCtD
Cyclobenzaprine—Syncope—Betamethasone—psoriatic arthritis	0.000164	0.00196	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Prednisone—psoriatic arthritis	0.000163	0.00196	CcSEcCtD
Cyclobenzaprine—Sweating—Methotrexate—psoriatic arthritis	0.000163	0.00196	CcSEcCtD
Cyclobenzaprine—Shock—Triamcinolone—psoriatic arthritis	0.000162	0.00194	CcSEcCtD
Cyclobenzaprine—Insomnia—Prednisolone—psoriatic arthritis	0.000162	0.00194	CcSEcCtD
Cyclobenzaprine—Alopecia—Prednisone—psoriatic arthritis	0.000161	0.00194	CcSEcCtD
Cyclobenzaprine—Shock—Methylprednisolone—psoriatic arthritis	0.000161	0.00193	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000161	0.00193	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000161	0.00193	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Prednisolone—psoriatic arthritis	0.00016	0.00192	CcSEcCtD
Cyclobenzaprine—Tachycardia—Triamcinolone—psoriatic arthritis	0.00016	0.00192	CcSEcCtD
Cyclobenzaprine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00016	0.00192	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000159	0.0019	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000159	0.0019	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000158	0.0019	CcSEcCtD
Cyclobenzaprine—Convulsion—Dexamethasone—psoriatic arthritis	0.000158	0.0019	CcSEcCtD
Cyclobenzaprine—Convulsion—Betamethasone—psoriatic arthritis	0.000158	0.0019	CcSEcCtD
Cyclobenzaprine—Hypertension—Dexamethasone—psoriatic arthritis	0.000158	0.00189	CcSEcCtD
Cyclobenzaprine—Hypertension—Betamethasone—psoriatic arthritis	0.000158	0.00189	CcSEcCtD
Cyclobenzaprine—Myalgia—Betamethasone—psoriatic arthritis	0.000155	0.00187	CcSEcCtD
Cyclobenzaprine—Myalgia—Dexamethasone—psoriatic arthritis	0.000155	0.00187	CcSEcCtD
Cyclobenzaprine—Anxiety—Dexamethasone—psoriatic arthritis	0.000155	0.00186	CcSEcCtD
Cyclobenzaprine—Anxiety—Betamethasone—psoriatic arthritis	0.000155	0.00186	CcSEcCtD
Cyclobenzaprine—Discomfort—Dexamethasone—psoriatic arthritis	0.000154	0.00184	CcSEcCtD
Cyclobenzaprine—Discomfort—Betamethasone—psoriatic arthritis	0.000154	0.00184	CcSEcCtD
Cyclobenzaprine—Hypotension—Methylprednisolone—psoriatic arthritis	0.000153	0.00184	CcSEcCtD
Cyclobenzaprine—Hepatitis—Methotrexate—psoriatic arthritis	0.000153	0.00183	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Methotrexate—psoriatic arthritis	0.000152	0.00182	CcSEcCtD
Cyclobenzaprine—Vision blurred—Prednisone—psoriatic arthritis	0.00015	0.0018	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00015	0.0018	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000149	0.00179	CcSEcCtD
Cyclobenzaprine—Oedema—Dexamethasone—psoriatic arthritis	0.000149	0.00179	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000149	0.00179	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000149	0.00179	CcSEcCtD
Cyclobenzaprine—Oedema—Betamethasone—psoriatic arthritis	0.000149	0.00179	CcSEcCtD
Cyclobenzaprine—Insomnia—Triamcinolone—psoriatic arthritis	0.000149	0.00178	CcSEcCtD
Cyclobenzaprine—Insomnia—Methylprednisolone—psoriatic arthritis	0.000148	0.00178	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000148	0.00177	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000148	0.00177	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000147	0.00177	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000147	0.00177	CcSEcCtD
Cyclobenzaprine—Shock—Dexamethasone—psoriatic arthritis	0.000147	0.00176	CcSEcCtD
Cyclobenzaprine—Shock—Betamethasone—psoriatic arthritis	0.000147	0.00176	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000146	0.00176	CcSEcCtD
Cyclobenzaprine—Agitation—Prednisone—psoriatic arthritis	0.000146	0.00175	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000146	0.00175	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000146	0.00175	CcSEcCtD
Cyclobenzaprine—Tachycardia—Betamethasone—psoriatic arthritis	0.000145	0.00174	CcSEcCtD
Cyclobenzaprine—Tachycardia—Dexamethasone—psoriatic arthritis	0.000145	0.00174	CcSEcCtD
Cyclobenzaprine—Angioedema—Prednisone—psoriatic arthritis	0.000145	0.00174	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000145	0.00173	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000144	0.00173	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000144	0.00173	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000144	0.00173	CcSEcCtD
Cyclobenzaprine—Malaise—Prednisone—psoriatic arthritis	0.000143	0.00172	CcSEcCtD
Cyclobenzaprine—Vertigo—Prednisone—psoriatic arthritis	0.000143	0.00171	CcSEcCtD
Cyclobenzaprine—Syncope—Prednisone—psoriatic arthritis	0.000143	0.00171	CcSEcCtD
Cyclobenzaprine—Tinnitus—Methotrexate—psoriatic arthritis	0.000142	0.00171	CcSEcCtD
Cyclobenzaprine—Anorexia—Dexamethasone—psoriatic arthritis	0.000142	0.0017	CcSEcCtD
Cyclobenzaprine—Anorexia—Betamethasone—psoriatic arthritis	0.000142	0.0017	CcSEcCtD
Cyclobenzaprine—Urticaria—Prednisolone—psoriatic arthritis	0.000142	0.0017	CcSEcCtD
Cyclobenzaprine—Fatigue—Triamcinolone—psoriatic arthritis	0.000142	0.0017	CcSEcCtD
Cyclobenzaprine—Fatigue—Methylprednisolone—psoriatic arthritis	0.000141	0.0017	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Prednisone—psoriatic arthritis	0.00014	0.00168	CcSEcCtD
Cyclobenzaprine—Hypotension—Dexamethasone—psoriatic arthritis	0.000139	0.00167	CcSEcCtD
Cyclobenzaprine—Hypotension—Betamethasone—psoriatic arthritis	0.000139	0.00167	CcSEcCtD
Cyclobenzaprine—Convulsion—Prednisone—psoriatic arthritis	0.000138	0.00165	CcSEcCtD
Cyclobenzaprine—Hypertension—Prednisone—psoriatic arthritis	0.000137	0.00165	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000136	0.00163	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000136	0.00163	CcSEcCtD
Cyclobenzaprine—Myalgia—Prednisone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Anxiety—Prednisone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Alopecia—Methotrexate—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Insomnia—Dexamethasone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Insomnia—Betamethasone—psoriatic arthritis	0.000135	0.00162	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000134	0.00161	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000134	0.00161	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Betamethasone—psoriatic arthritis	0.000134	0.00161	CcSEcCtD
Cyclobenzaprine—Discomfort—Prednisone—psoriatic arthritis	0.000134	0.0016	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000132	0.00158	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000131	0.00157	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Betamethasone—psoriatic arthritis	0.000131	0.00157	CcSEcCtD
Cyclobenzaprine—Urticaria—Triamcinolone—psoriatic arthritis	0.000131	0.00157	CcSEcCtD
Cyclobenzaprine—Urticaria—Methylprednisolone—psoriatic arthritis	0.00013	0.00156	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—psoriatic arthritis	0.00013	0.00156	CcSEcCtD
Cyclobenzaprine—Oedema—Prednisone—psoriatic arthritis	0.00013	0.00156	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00013	0.00156	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00013	0.00155	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00013	0.00155	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Betamethasone—psoriatic arthritis	0.00013	0.00155	CcSEcCtD
Cyclobenzaprine—Fatigue—Dexamethasone—psoriatic arthritis	0.000129	0.00154	CcSEcCtD
Cyclobenzaprine—Fatigue—Betamethasone—psoriatic arthritis	0.000129	0.00154	CcSEcCtD
Cyclobenzaprine—Shock—Prednisone—psoriatic arthritis	0.000128	0.00153	CcSEcCtD
Cyclobenzaprine—Tachycardia—Prednisone—psoriatic arthritis	0.000127	0.00152	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000125	0.00151	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—psoriatic arthritis	0.000125	0.0015	CcSEcCtD
Cyclobenzaprine—Anorexia—Prednisone—psoriatic arthritis	0.000124	0.00148	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000123	0.00148	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000123	0.00147	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000123	0.00147	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000122	0.00146	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000122	0.00146	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000121	0.00145	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000121	0.00145	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—psoriatic arthritis	0.00012	0.00144	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—psoriatic arthritis	0.000119	0.00143	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—psoriatic arthritis	0.000119	0.00143	CcSEcCtD
Cyclobenzaprine—Urticaria—Dexamethasone—psoriatic arthritis	0.000118	0.00142	CcSEcCtD
Cyclobenzaprine—Urticaria—Betamethasone—psoriatic arthritis	0.000118	0.00142	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000118	0.00142	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisolone—psoriatic arthritis	0.000118	0.00142	CcSEcCtD
Cyclobenzaprine—Asthenia—Triamcinolone—psoriatic arthritis	0.000118	0.00141	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000118	0.00141	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Betamethasone—psoriatic arthritis	0.000118	0.00141	CcSEcCtD
Cyclobenzaprine—Asthenia—Methylprednisolone—psoriatic arthritis	0.000118	0.00141	CcSEcCtD
Cyclobenzaprine—Insomnia—Prednisone—psoriatic arthritis	0.000117	0.00141	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Prednisone—psoriatic arthritis	0.000117	0.0014	CcSEcCtD
Cyclobenzaprine—Pruritus—Triamcinolone—psoriatic arthritis	0.000116	0.00139	CcSEcCtD
Cyclobenzaprine—Pruritus—Methylprednisolone—psoriatic arthritis	0.000116	0.00139	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—psoriatic arthritis	0.000115	0.00138	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Prednisone—psoriatic arthritis	0.000114	0.00137	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—psoriatic arthritis	0.000113	0.00136	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—psoriatic arthritis	0.000113	0.00136	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Prednisone—psoriatic arthritis	0.000113	0.00135	CcSEcCtD
Cyclobenzaprine—Rash—Prednisolone—psoriatic arthritis	0.000113	0.00135	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisolone—psoriatic arthritis	0.000113	0.00135	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000112	0.00135	CcSEcCtD
Cyclobenzaprine—Fatigue—Prednisone—psoriatic arthritis	0.000112	0.00134	CcSEcCtD
Cyclobenzaprine—Headache—Prednisolone—psoriatic arthritis	0.000112	0.00134	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—psoriatic arthritis	0.000112	0.00134	CcSEcCtD
Cyclobenzaprine—Constipation—Prednisone—psoriatic arthritis	0.000111	0.00133	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—psoriatic arthritis	0.000109	0.00131	CcSEcCtD
Cyclobenzaprine—Dizziness—Triamcinolone—psoriatic arthritis	0.000109	0.0013	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000108	0.0013	CcSEcCtD
Cyclobenzaprine—Dizziness—Methylprednisolone—psoriatic arthritis	0.000108	0.0013	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Prednisone—psoriatic arthritis	0.000107	0.00128	CcSEcCtD
Cyclobenzaprine—Asthenia—Betamethasone—psoriatic arthritis	0.000107	0.00128	CcSEcCtD
Cyclobenzaprine—Asthenia—Dexamethasone—psoriatic arthritis	0.000107	0.00128	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000106	0.00127	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000106	0.00127	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisolone—psoriatic arthritis	0.000106	0.00127	CcSEcCtD
Cyclobenzaprine—Pruritus—Dexamethasone—psoriatic arthritis	0.000105	0.00126	CcSEcCtD
Cyclobenzaprine—Pruritus—Betamethasone—psoriatic arthritis	0.000105	0.00126	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000105	0.00126	CcSEcCtD
Cyclobenzaprine—Vomiting—Triamcinolone—psoriatic arthritis	0.000104	0.00125	CcSEcCtD
Cyclobenzaprine—Vomiting—Methylprednisolone—psoriatic arthritis	0.000104	0.00125	CcSEcCtD
Cyclobenzaprine—Rash—Triamcinolone—psoriatic arthritis	0.000104	0.00124	CcSEcCtD
Cyclobenzaprine—Dermatitis—Triamcinolone—psoriatic arthritis	0.000103	0.00124	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—psoriatic arthritis	0.000103	0.00124	CcSEcCtD
Cyclobenzaprine—Rash—Methylprednisolone—psoriatic arthritis	0.000103	0.00124	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000103	0.00124	CcSEcCtD
Cyclobenzaprine—Urticaria—Prednisone—psoriatic arthritis	0.000103	0.00124	CcSEcCtD
Cyclobenzaprine—Headache—Triamcinolone—psoriatic arthritis	0.000103	0.00123	CcSEcCtD
Cyclobenzaprine—Headache—Methylprednisolone—psoriatic arthritis	0.000103	0.00123	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Prednisone—psoriatic arthritis	0.000103	0.00123	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000102	0.00122	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Betamethasone—psoriatic arthritis	0.000102	0.00122	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—psoriatic arthritis	0.000101	0.00122	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	9.88e-05	0.00119	CcSEcCtD
Cyclobenzaprine—Dizziness—Dexamethasone—psoriatic arthritis	9.86e-05	0.00118	CcSEcCtD
Cyclobenzaprine—Dizziness—Betamethasone—psoriatic arthritis	9.86e-05	0.00118	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—psoriatic arthritis	9.81e-05	0.00118	CcSEcCtD
Cyclobenzaprine—Nausea—Triamcinolone—psoriatic arthritis	9.76e-05	0.00117	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—psoriatic arthritis	9.74e-05	0.00117	CcSEcCtD
Cyclobenzaprine—Nausea—Methylprednisolone—psoriatic arthritis	9.74e-05	0.00117	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—psoriatic arthritis	9.67e-05	0.00116	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—psoriatic arthritis	9.64e-05	0.00116	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisone—psoriatic arthritis	9.56e-05	0.00115	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—psoriatic arthritis	9.55e-05	0.00115	CcSEcCtD
Cyclobenzaprine—Vomiting—Dexamethasone—psoriatic arthritis	9.48e-05	0.00114	CcSEcCtD
Cyclobenzaprine—Vomiting—Betamethasone—psoriatic arthritis	9.48e-05	0.00114	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—psoriatic arthritis	9.43e-05	0.00113	CcSEcCtD
Cyclobenzaprine—Rash—Betamethasone—psoriatic arthritis	9.4e-05	0.00113	CcSEcCtD
Cyclobenzaprine—Rash—Dexamethasone—psoriatic arthritis	9.4e-05	0.00113	CcSEcCtD
Cyclobenzaprine—Dermatitis—Betamethasone—psoriatic arthritis	9.39e-05	0.00113	CcSEcCtD
Cyclobenzaprine—Dermatitis—Dexamethasone—psoriatic arthritis	9.39e-05	0.00113	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—psoriatic arthritis	9.35e-05	0.00112	CcSEcCtD
Cyclobenzaprine—Headache—Betamethasone—psoriatic arthritis	9.34e-05	0.00112	CcSEcCtD
Cyclobenzaprine—Headache—Dexamethasone—psoriatic arthritis	9.34e-05	0.00112	CcSEcCtD
Cyclobenzaprine—Asthenia—Prednisone—psoriatic arthritis	9.31e-05	0.00112	CcSEcCtD
Cyclobenzaprine—Pruritus—Prednisone—psoriatic arthritis	9.18e-05	0.0011	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—psoriatic arthritis	8.94e-05	0.00107	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Prednisone—psoriatic arthritis	8.88e-05	0.00107	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	8.87e-05	0.00106	CcSEcCtD
Cyclobenzaprine—Nausea—Dexamethasone—psoriatic arthritis	8.85e-05	0.00106	CcSEcCtD
Cyclobenzaprine—Nausea—Betamethasone—psoriatic arthritis	8.85e-05	0.00106	CcSEcCtD
Cyclobenzaprine—Urticaria—Methotrexate—psoriatic arthritis	8.62e-05	0.00103	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisone—psoriatic arthritis	8.58e-05	0.00103	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—psoriatic arthritis	8.58e-05	0.00103	CcSEcCtD
Cyclobenzaprine—Vomiting—Prednisone—psoriatic arthritis	8.25e-05	0.00099	CcSEcCtD
Cyclobenzaprine—Rash—Prednisone—psoriatic arthritis	8.18e-05	0.000982	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisone—psoriatic arthritis	8.18e-05	0.000981	CcSEcCtD
Cyclobenzaprine—Headache—Prednisone—psoriatic arthritis	8.13e-05	0.000975	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methotrexate—psoriatic arthritis	7.99e-05	0.000959	CcSEcCtD
Cyclobenzaprine—Asthenia—Methotrexate—psoriatic arthritis	7.78e-05	0.000934	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisone—psoriatic arthritis	7.71e-05	0.000925	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—psoriatic arthritis	7.68e-05	0.000921	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—psoriatic arthritis	7.42e-05	0.00089	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—psoriatic arthritis	7.17e-05	0.00086	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—psoriatic arthritis	6.9e-05	0.000827	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—psoriatic arthritis	6.84e-05	0.00082	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—psoriatic arthritis	6.83e-05	0.00082	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—psoriatic arthritis	6.8e-05	0.000815	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—psoriatic arthritis	6.44e-05	0.000773	CcSEcCtD
